Regional sympathetic effects of low-dose clonidine in heart failure

Hypertension

Volumn 41, Issue 3 I, 2003, Pages 553-557

  Aggarwal, Anuradha ^a   Esler, Murray D ^a   Morris, Margaret J ^a   Lambert, Gavin ^a   Kaye, David M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Clonidine; Heart failure; Norepinephrine; Renal

Indexed keywords

BRAIN MONOAMINE; CLONIDINE; NEUROPEPTIDE Y; NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; HEART; HUMAN; KIDNEY; LOW DRUG DOSE; MALE; MONOAMINE METABOLISM; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN SECRETION; SYMPATHETIC TONE;

AGED; BRAIN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYOCARDIUM; NEUROPEPTIDE Y; NOREPINEPHRINE; ORGAN SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 0037336614     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000055779.93635.A2     Document Type: Article

References (32)

1. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
2. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
4. Haass M. Neuropeptide Y: a cardiac sympathetic cotransmitter? In: Goldstein DS, Eisenhofer G, McCarty R, eds. Catecholamines: Bridging Basic Science With Clinical Medicine. San Diego, Calif: Academic Press; 1998:129-132.
5. Campbell DJ, Aggarwal A, Esler M, Kaye D. β-Blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001;358:1609-1610.
6. Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol. 1990;38(suppl 2):S96-S100.
7. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570-578.
8. Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, Esler M. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation. 1995;92:1813-1818.
9. Isaac L. Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol. 1980;2(suppl 1):S5-S19.
10. 2-adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol. 2001;37:1246-1251.
11. Lang CC, Rayos GH, Chomsky DB, Wood AJ, Wilson JR. Effect of sympathoinhibition on exercise performance in patients with heart failure. Circulation. 1997;96:238-245.
12. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H. Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. Hypertension. 1995;26:719-724.
13. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension. 2001;38:286-291.
14. Azevedo ER, Newton GE, Parker JD. Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. J Am Coll Cardiol. 1999;33:186-191.
15. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. J Am Coll Cardiol. 2000;35:398-404.
16. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL. Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther. 1981;30:724-728.
17. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3-20.
18. Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ. Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst. 1988;24:1-14.
19. Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, Wing LM, Chalmers JP. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986;17:143-149.
20. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991;325:618-624.
21. Esler M, Dudley F, Jennings G, Debinski H, Lambert G, Jones P, Crotty B, Colman J, Willett I. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med. 1992;116:446-455.
22. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
23. Dupont AG. Carvedilol and the kidney. Clin Investig. 1992;70(suppl 1):S127-S131.
24. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104:2194-2199.
25. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, Brown MR. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86:43-48.
26. Hokfelt T, Johansson O, Goldstein M. Chemical anatomy of the brain. Science. 1984;225:1326-1334.
27. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev. 1983; 63:844-914.
28. Braestrup C. Effects of phenoxybenzamine, aceperone and clonidine on the level of 3-methoxy-4-hydroxyphenylglycol (MOPEG) in rat brain. J Pharm Pharmacol. 1974;26:139-141.
29. Maas JW, Hattox SE, Landis DH, Roth RH. A direct method for studying 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) production by brain in awake animals. Eur J Pharmacol. 1977;46:221-228.
30. Lambert GW, Kaye DM, Thompson JM, Turner AG, Cox HS, Vaz M, Jennings GL, Wallin P, Esler MD. Internal jugular venous spillover of noradrenaline and metabolites and their association with sympathetic nervous activity. Acta Physiol Scand. 1998;163:155-163.
31. Elam M, Yao T, Svensson TH, Thoren P. Regulation of locus coeruleus neurons and splanchnic, sympathetic nerves by cardiovascular afferents. Brain Res. 1984;290:281-287.
32. Ferrier C, Jennings GL, Eisenhofer G, Lambert G, Cox HS, Kalff V, Kelly M, Esler MD. Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. J Hypertens. 1993;11:1217-1227.